key: cord-0990659-cq7autdd
authors: Jamilloux, Yvan; Gerfaud-Valentin, Mathieu; Sève, Pascal
title: Intravenous anakinra for cytokine storm syndromes
date: 2020-07-21
journal: Lancet Rheumatol
DOI: 10.1016/s2665-9913(20)30225-3
sha: 1f1f13ec228b7b6e823cc4c5bb7738f940326637
doc_id: 990659
cord_uid: cq7autdd

nan

In their Viewpoint on cytokine storm syndromes, Puja Mehta and colleagues 1 stated that "there is a critical need and growing call for unified nomen clature (such as cytokine storm syn dromes)". Although we agree that a multidisciplinary effort is needed to analyse and classify these conditions, we have concerns about unifying them all under a single umbrella. Indeed, cytokine storm syndromes currently encompass several differ ent conditions with extremely varied causes, pathophysiological processes, or prominant cytokines. Although they manifest with similar symptoms, they might have only one truly common feature: hypercytokinaemia. For instance, haemophagocytic lympho histiocytosis might be the con se quence of deficient cyto toxic cells (primary and some virally induced haemophagocytic lympho histiocytosis), 2 hyperactivation of the inflam masome pathway (NLRC4 associated macrophage activation syndrome), 3 or a yettobedefined com bination of these factors (eg, Still's disease spectrum). All of these con ditions are characterised by elevated plasma concentrations of IL1 family cytokines (IL1β and IL18) and tissue haemophagocytosis. Alternatively, cytokine release syndrome secondary to chimeric antigen receptor Tcell therapy has been linked to high IFNγ release, whereas the involvement of the IL1 family cytokines seemed less prominent. 4 Lastly, it is note worthy that cytokine storm has attracted great interest, as a result of its description as a major determinant of COVID19 outcomes. Yet, despite there being no definitive understanding of its immunopathology, a hallmark of COVID19associated cytokine storms seems to be prominent IL6 elevation, with only 25% of patients showing evidence for IL1driven macrophage activation or haemophagocytosis. 5 In the remaining 75% of patients, the disease has been compared with complex immune dysregulation seen in patients with sepsis (ie, prominent role for IL6, low HLADR expression, and lymphopenia).

These considerations are important because the clinicians' armamentarium is now large enough to offer the best targeted therapies in these different contexts (ie, inhibitors of IL1, IFNγ, or IL6). Defining criteria for choos ing one treatment over the other, or instead of a lesstargeted therapy (eg, corticosteroids or Janus kinase inhibitors) will certainly be one of the challenges of clinical trials in the near future.

Overall, we suggest that if an inter national, multidisciplinary effort is mounted to unify cytokine storm syndromes within one spectrum, this nomenclature will have to be sub divided on the basis of the cause, the supposed pathophysiology, and the pivotal cytokines involved. In daily practice, the availability of rapid immune monitoring tests (eg, cytokine multi plex assays) would therefore be of utmost interest.

We declare no competing interests. *Yvan Jamilloux, Mathieu Gerfaud-Valentin, Pascal Sève yvan.jamilloux@chu-lyon.fr

Hopital de la CroixRousse

Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome

Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment

An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome

Mechanisms and management of chimeric antigen receptor Tcell therapy related toxicities

Complex immune dysregulation in COVID19 patients with severe respiratory failure